We are live on ! Find out more
AEPBI

AH Equity Partners Bio III Portfolio holdings

AUM $95M
1-Year Est. Return 50.1%
This Fund
S&P 500
This Quarter Est. Return
-31.25%
1 Year Est. Return
-50.1%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$131M
AUM Growth
–
Cap. Flow
+$181M
Cap. Flow %
138.4%
Top 10 Hldgs %
100%
Holding
1
New
1
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
EQRX
EQRx, Inc. Common Stock
EQRX
+$181M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EQRX
1
DELISTED
EQRx, Inc. Common Stock
EQRX
$131M 100%
+19,192,015
New +$181M

Similar funds

SC
Sarissa Consulting Santa Monica, California $96.9M AUM 29.32% 1-Year Est. Return
SCA
Spearhead Capital Advisors Wellington, Florida $92.3M AUM 18.16% 1-Year Est. Return
WIM
Wilen Investment Management Bonita Springs, Florida $98.1M AUM 2.08% 1-Year Est. Return
LAM
LFS Asset Management San Ramon, California $99.1M AUM
AAM
Artha Asset Management Hoboken, New Jersey $90.3M AUM 27.65% 1-Year Est. Return
MW
Milestone Wealth Buffalo, New York $89.5M AUM 17.2% 1-Year Est. Return
NIM
NuWave Investment Management Parsippany, New Jersey $87.2M AUM 38.54% 1-Year Est. Return
EFEM
Eos Focused Equity Management New York $84.5M AUM 17.48% 1-Year Est. Return

AH Equity Partners Bio III's Q4 2021 Portfolio in Review

Q4 2021 is the first quarter with a 13F filing on record for AH Equity Partners Bio III, which disclosed 1 position worth $131M. Its ten largest holdings account for 100% of the portfolio.

Its largest position is EQRx, Inc. Common Stock: 19,192,015 shares worth $131M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • AH Equity Partners Bio III's largest Q4 2021 buy was EQRx, Inc. Common Stock: 19,192,015 shares worth $131M.
  • AH Equity Partners Bio III's ten largest holdings make up 100% of its $131M portfolio in Q4 2021.
  • AH Equity Partners Bio III disclosed 1 position in Q4 2021, its first 13F filing on record.

Based on AH Equity Partners Bio III's 13F filing for Q4 2021, filed 14 Feb 2022.